Authors: Woodworth, TG Furst, DE Strand, V Kempeni, J Fenner, H Lau, CS Miller, F Day, R Lipani, J Brooks, P

Citation: Tg. Woodworth et al., Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies, J RHEUMATOL, 28(5), 2001, pp. 1163-1169

Authors: Reinhart, K Menges, T Gardlund, B Zwaveling, JH Smithes, M Vincent, JL Tellado, JM Salgado-Remigio, A Zimlichman, R Withington, S Tschaikowsky, K Brase, R Damas, P Kupper, H Kempeni, J Eiselstein, J Kaul, M

Citation: K. Reinhart et al., Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study, CRIT CARE M, 29(4), 2001, pp. 765-769

Authors: Kempeni, J

Citation: J. Kempeni, Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonalantibody, ANN RHEUM D, 59, 2000, pp. 44-45

Authors: Kempeni, J

Citation: J. Kempeni, Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7, ANN RHEUM D, 58, 1999, pp. 70-72